ASX - By Stock
|
AVR |
Re:
Ann: Response to Aware Query
|
|
wessomart
|
81 |
35K |
4 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
81
|
35K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Response to Aware Query
|
|
wessomart
|
81 |
35K |
3 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
81
|
35K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Response to Aware Query
|
|
wessomart
|
81 |
35K |
9 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
81
|
35K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Response to Aware Query
|
|
wessomart
|
81 |
35K |
7 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
81
|
35K
|
7
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Response to Aware Query
|
|
wessomart
|
81 |
35K |
9 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
81
|
35K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
RaNa details
|
|
wessomart
|
1 |
1.2K |
1 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
1
|
1.2K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
1 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
350
|
143K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
2 |
08/05/17 |
08/05/17 |
ASX - By Stock
|
350
|
143K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
8 |
07/05/17 |
07/05/17 |
ASX - By Stock
|
350
|
143K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
7 |
07/05/17 |
07/05/17 |
ASX - By Stock
|
350
|
143K
|
7
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
4 |
06/05/17 |
06/05/17 |
ASX - By Stock
|
350
|
143K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
8 |
06/05/17 |
06/05/17 |
ASX - By Stock
|
350
|
143K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Tissue Engineering v. Immunotherapy
|
|
wessomart
|
18 |
6.1K |
2 |
06/05/17 |
06/05/17 |
ASX - By Stock
|
18
|
6.1K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
0 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
8 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
8 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
7 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
7
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
3 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
11 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
11
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
5 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
4 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
20 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
20
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
2 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
4 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
1 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
wessomart
|
350 |
143K |
13 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
13
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
8 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
296
|
158K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
6 |
03/05/17 |
03/05/17 |
ASX - By Stock
|
296
|
158K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
2 |
03/05/17 |
03/05/17 |
ASX - By Stock
|
296
|
158K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
14 |
03/05/17 |
03/05/17 |
ASX - By Stock
|
296
|
158K
|
14
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
5 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
9 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
9
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
2 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
6 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
1 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
2 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
13 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
13
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
wessomart
|
134 |
50K |
7 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
50K
|
7
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
0 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
5 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
1 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
4 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
8 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
8 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
8
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
1 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
5 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
6 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
wessomart
|
296 |
158K |
10 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
10
|
|
ASX - By Stock
|
AVR |
Re:
"Take a Closer Look"
|
|
wessomart
|
1.2K |
445K |
2 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
1.2K
|
445K
|
2
|
|